Fore Genomics Adopts DNAnexus Platform to Access and Analyze Whole-Genome Newborn Screening Data
Comprehensive cloud platform provides industry-leading data quality, security, privacy, and compliance for ongoing service that screens for more than 300 inherited conditions with automated annual re-analysis
MOUNTAIN VIEW, Calif., and LA JOLLA, Calif. — July 25, 2023 — DNAnexus Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced that Fore Genomics, a proactive genetic testing company designed for healthy newborns, infants, and children, is using the DNAnexus platform for its FORESITE 360 test. The purpose-built and scalable DNAnexus platform enables Fore Genomics to meet with current and future security, quality, and compliance requirements as they evolve over time.
The FORESITE 360 test is a groundbreaking health information service that creates a complete genomic profile using a baby’s DNA. The clinical whole-genome sequencing test was designed to sequence more than 22,000 genes and screen for more than 300 inherited conditions and for pharmacogenomic response to more than 40 common medication types. After the initial analysis, the child’s profile will be reanalyzed every year as part of the ongoing service to glean the latest genomic insights. This approach offers a better understanding of current medical problems, insights to guide preventive healthcare decisions, and critical information for relatives and future generations.
“Our FORESITE 360 test is the product of years spent in the genomics industry seeing new discoveries linking risk of disease to genetic variation with limited clinical utility,” said Matt Pelo, Founder and CEO of Fore Genomics. “Protecting our customer data is paramount to what we do, and DNAnexus offers the industry's most stringent security, privacy, and compliance platform. This information will help unlock a lifetime of health insights.”
Today, DNAnexus has more than 40,000 registered users across 48 countries and actively manages and supports more than 80 petabytes of complex proteomic, genomic, multi-omic, and clinical datasets on behalf of a growing network of collaborators. The company provides a comprehensive cloud platform designed to meet the most rigorous standards and is compliant with ISO27001, NIST 800 framework, GDPR, GxP/ICH, CAP/CLIA regulations, and more.
“Fore Genomics is poised to transform patient care as we know it by providing parents with a complete map of their baby’s DNA and the opportunity to invest in their long-term health,” said Richard Daly, CEO at DNAnexus. “I’m proud to say that DNAnexus has built the world’s most secure, trusted cloud platform and global network for scientific collaboration and accelerated discovery. Fore Genomics joins a growing list of users that includes large scale biobanks as well as leading pharmaceutical, clinical diagnostic, academic research, and government organizations.”
All sequencing for the FORESITE 360 test is conducted in the US in collaboration with a CAP-accredited, CLIA-compliant clinical services lab. FORESITE 360 also provides access to licensed genetic counselors for both pre and post-test consultations. For more information on the FORESITE 360 test, please visit www.foresite360.com.
About Fore Genomics
Fore Genomics leading product, FORESITE 360, is a predisposition test for healthy newborns, infants, and children. FORESITE 360 provides clinically actionable information on more than 300 diseases that if known early can be clinically managed to help people live healthier lives. FORESITE 360 is available at www.foresite360.com and in pediatric and OB/GYN offices throughout the country. For more information, please visit www.foregenomics.com or follow@foregenomics on Twitter, Meta and/or LinkedIn.
DNAnexus is a leading provider of secure, scalable, and intuitive biomedical data analysis software and bioinformatics applications for the life sciences and healthcare communities. The company actively manages and supports more than 80 petabytes of complex genomic, multi-omic, and clinical datasets on behalf of a growing network of collaborations with large-scale biobanks, as well as leading pharmaceutical, clinical diagnostic, academic research, and government organizations. Scientists across 48 countries are now using the highly collaborative, cloud-based, end-to-end platform to gain data-driven insights that can advance scientific discovery, accelerate precision medicine, and improve patient care.For more information on DNAnexus, please visit www.dnanexus.com or follow the company @DNAnexus.